RxDoctor Payments Data

Jonathan Cropp

Nurse Practitioner · Shoals, INNPI 1063859643

Payments from drug & device makers

$475in general payments, 2019–2025

Across 35 payments — averaging $13.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$151
  • AbbVie$143
  • Lilly USA, LLC$44
  • Bayer$28
  • E.r. Squibb & Sons, L.L.C.$24
  • Takeda Pharmaceuticals U.S.A., Inc.$19
  • plus $66 from 5 others

What the payments were for

  • Food & beverage$45195%
  • Education$245%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$475 in reported general payments places this provider in the 60th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$1,827
Medicare patients
61
Services billed
110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin169$188,405
OzempicSemaglutide144$183,346
MounjaroTirzepatide111$140,285
Trelegy ElliptaFluticasone/Umeclidin/Vilanter130$96,331
IngrezzaValbenazine Tosylate11$88,281
EliquisApixaban83$87,608
TrulicityDulaglutide63$67,442
Tresiba Flextouch U-100Insulin Degludec55$31,049
XareltoRivaroxaban28$25,924
FarxigaDapagliflozin Propanediol20$23,898
RexultiBrexpiprazole12$20,178
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr36$18,869
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$14,963
UbrelvyUbrogepant14$12,834
MyrbetriqMirabegron18$12,750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$44$207,727174 claims
Boehringer IngelheimJardiance, Synjardy Xr$17$195,611181 claims
Novo NordiskOzempic$151$183,346144 claims
Neurocrine Biosciences, Inc.Ingrezza$15$88,28111 claims
AbbVieUbrelvy, Synthroid$143$16,75358 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Shoals

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →